Glancy Prongay & Murray Reminds Investors of the January 2, 2018 Deadline in the Class Action Lawsuit Against Genocea Biosciences, Inc. (GNCA)

LOS ANGELES--()--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the January 2, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Genocea Biosciences, Inc. (“Genocea” or the “Company”) (NASDAQ: GNCA) securities between August 4, 2016 and September 25, 2017, inclusive (the “Class Period”). Genocea investors have until January 2, 2018 to file a lead plaintiff motion. To obtain information or participate in the class action, please visit the Genocea page on our website at www.glancylaw.com/case/genocea-biosciences-inc.

Investors suffering losses on their Genocea investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

On September 25, 2017, Genocea disclosed that it was halting spending and activities on GEN-003 and exploring strategic alternatives for the drug. The Company also announced that it was cutting 40% of its workforce. On this news, shares of Genocea fell $4.08, or 76.5%, to close at $1.25 on September 26, 2017, thereby injuring investors.

The complaint filed in this class action alleges that the Company and certain executives issued false and misleading statements to investors, including in filings with the U.S. Securities and Exchange Commission (“SEC”). Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s finances were insufficient to support Phase 3 trials of GEN-003; (ii) accordingly, Genocea had overstated the prospects for GEN-003; and (iii) as a result of the foregoing, Genocea’s public statements were materially false and misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Genocea during the Class Period you may move the Court no later than January 2, 2018 to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

Release Summary

Glancy Prongay & Murray Reminds Investors of the January 2, 2018 Deadline in the Class Action Lawsuit Against Genocea Biosciences, Inc. (GNCA)

$Cashtags

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com